不列颠哥伦比亚省对用于治疗稀有高胆固醇紊乱的基因定向药物的公共资金进行权衡,2026年初作出决定。 British Columbia weighs public funding for a gene-targeting drug treating rare high-cholesterol disorder, with decision due early 2026.

不列颠哥伦比亚省正在评估是否公开资助一种新的药物 给那些患有罕见的遗传胆固醇紊乱 家庭超胆固醇性贫血的人 尤其是那些不能忍受statins的人。 British Columbia is evaluating whether to publicly fund a new drug for people with a rare genetic cholesterol disorder, familial hypercholesterolemia, especially those who can't tolerate statins. 治疗针对根本遗传原因,在减少心脏病和中风风险方面已显示出希望。 The treatment targets the root genetic cause and has shown promise in reducing heart disease and stroke risk. 官员正在审查其有效性、安全和成本,预计将于2026年初作出决定。 Officials are reviewing its effectiveness, safety, and cost, with a decision expected in early 2026. 尽管费用高昂,但这项举措旨在改善稀有疾病获得精密药品的机会。 The move aims to improve access to precision medicine for rare diseases despite high costs.